Adeona Becomes Synthetic Biologics, Inc.Ann Arbor-based Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) said Thursday that it had received shareholder approval to change its corporate name to Synthetic Biologics Inc.
HR Notices From February 7The latest staffing, boardroom and leadership changes at Michigan's technology-focused companies and institutions
Adeona Names New Managers, Eyes Name ChangeAdeona Pharmaceuticals Inc. has swapped bosses as it continues testing new drugs for multiple sclerosis, fibromyalgia and Lou Gehrig's disease. It's also considering a new business focus and a name change.
Adeona Reports Positive Study Results For Zinc Treatment Of ALSPharma startup Adeona and its research partner report no safety issues related to high doses of zinc to slow the effects of Lou Gehrig's Disease
HR Notices From November 2The latest personnel, leadership and boardroom news from Michigan's technology-focused companies and institutions
Chardan Capital Markets Initiates Research Coverage of AdeonaAdeona Pharmaceuticals Inc. (NYSE: AEN), announced Thursday that Chardan Capital Markets initiated independent equity research coverage of the company with a "Buy" rating and a 12-month price target of $1 per share.
HR Notices From August 25The latest personnel and boardroom announcements from Michigan's technology-focused companies and institutions
Adeona Loss Grows, But Milestones ReachedAnn Arbor-based Adeona Pharmaceuticals Inc. (AMEX: AEN), a developer of medicines for serious central nervous system diseases, Monday reported its second quarter financial results for the period ended June 30, as well as updates since the beginning of the second quarter.
Ann Arbor Pharma To Offer New Cold TreatmentAnn Arbor-based Adeona Pharmaceuticals Inc. said it will commercialize an oral zinc lozenge as a homeopathic over-the-counter treatment for the common cold under the brand name wellZin.
Adeona To Start New Trial Of Zinc-Based Therapy in Lou Gehrig's DiseaseAnn Arbor-based Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) announced Thursday that it has expanded its pipeline of proprietary zinc-based therapies to include a planned Phase IIb clinical trial of patients suffering from amyotrophic lateral sclerosis also known as Lou Gehrig's Disease.
Adeona Announces Positive Alzheimer's Subgroup AnalysisAnn Arbor-based Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) Thursday announced positive findings based on further analyses from the clinical study evaluating its product reaZin along with near-term plans for its Alzheimer's disease program.
Adeona Multiple Sclerosis Clinical Trial Receives $1.6M GrantAnn Arbor-based Adeona Pharmaceuticals Inc. announced Tuesday that after a scientific review, the ongoing clinical trial of its Trimesta oral estriol drug for multiple sclerosis has eeceived an additional $1,594,553 in grant funding from the National Institutes of Health's National Institute of Neurological Disorders and Stroke.
Adeona Gets Manufacturing Agreement For reaZinAnn Arbor-based Adeona Pharmaceuticals Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement with TG United, Inc. of Brooksville, Florida, to provide commercial-scale manufacturing capabilities for reaZin.
Adeona Gets Results From Alzheimer's Product CandidateAnn Arbor-based Adeona Pharmaceuticals Inc. late Thursday reported top-line results from its clinical study evaluating reaZin for the dietary management of Alzheimer's disease and mild cognitive impairment.
Adeona to Raise $3.5 Million In Stock OfferingAnn Arbor-based Adeona Pharmaceuticals Inc. said Thursday that it had an agreement for the sale of 1,688,782 shares of its common stock at $2.0725 per share to a new institutional investor in a registered direct offering for $3.5 million in gross proceeds